- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01119131
Effects of Vitamin D in Parkinson's Disease (PD)
8 februari 2016 bijgewerkt door: VA Office of Research and Development
The Effects of Vitamin D on Balance in Persons With PD
A trial to measure the effects of vitamin D (versus a placebo) on balance, gait, falls, strength, and cognition in persons with Parkinson's disease.
Studie Overzicht
Toestand
Voltooid
Interventie / Behandeling
Gedetailleerde beschrijving
The proposed study is a randomized, double-blinded, placebo controlled intervention trial to measure the effects of vitamin D at (10,000IU/day) versus placebo on balance and falls in Parkinson's disease.
The investigators will measure static, dynamic, and ambulatory balance, as well as strength, falls, and cognition before and after 16 weeks of therapy.
Dynamic posturography will be used to measure static and ambulatory balance, a device called iMOBILITY will measure a timed up and go, and strength will be measured with the Biodex machine checking knee flexion and extension.
Multiple quality of life and cognitive tests will also be performed.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
101
Fase
- Fase 2
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- VA Portland Health Care System, Portland, OR
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
50 jaar tot 99 jaar (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Parkinson's disease;
- ability to ambulate 50 feet;
- ability to cooperate with balance testing;
- vitamin D level less than 40ng/ml;
- balance problems;
- ability to walk 50 feet without the help of another person
Exclusion Criteria:
- MMSE < 25;
- another neurological or orthopedic deficit that in the examiner's opinion would affect testing;
- history of renal stones or hypercalcemia;
- unwillingness to not be on other vitamin D supplementation during the study
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Arm 1
Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
|
Vitamin D3 at 10,000 IU a day
1000mg calcium daily
|
|
Placebo-vergelijker: Arm 2
Will be on placebo and 1000mg of calcium.
|
1000mg calcium daily
A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)
Tijdsspanne: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves.
SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration
Tijdsspanne: Baseline and 16 weeks
|
This is a test that measures ambulatory balance and mobility.
The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down.
The turn duration is the average time to turn at the end of the 25 foot walk.
Longer duration of time (seconds) indicates more rigidity, a proxy measure for "ON" time in Parkinson's disease.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline and 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)
Tijdsspanne: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)
Tijdsspanne: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves.
SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)
Tijdsspanne: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in Cognition (Trail Making Test B-A)
Tijdsspanne: Baseline, 16 weeks
|
The Trail Making Test (TMT) consists of two parts (A & B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
The test provides information about visual search speed, scanning, speed of processing, and executive functioning.
Part A measures processing speed and part B measures executive functioning.
The TMT is time to complete each part of the test in seconds.
Higher scores indicate greater impairment.
Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function.
Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.
|
Baseline, 16 weeks
|
|
Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)
Tijdsspanne: Baseline, 16 weeks
|
The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD.
This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort).
The PDQ39 dimension scores are on a scale of 0 ("Never") to 4 ("Always/Cannot Do").
Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems.
For a single index figure to characterize the impact of Parkinson's disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed.
The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity.
Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.
|
Baseline, 16 weeks
|
|
Change in Parkinsonism as Measured by the UPDRS
Tijdsspanne: Baseline, 16 weeks
|
This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson's disease.
This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait.
A sum score represents motor function with higher values on this scale represent a more severe stage of the disease.
Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.
|
Baseline, 16 weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Amie Hiller, MD BS, VA Portland Health Care System, Portland, OR
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 mei 2011
Primaire voltooiing (Werkelijk)
1 januari 2015
Studie voltooiing (Werkelijk)
1 januari 2015
Studieregistratiedata
Eerst ingediend
23 april 2010
Eerst ingediend dat voldeed aan de QC-criteria
5 mei 2010
Eerst geplaatst (Schatting)
7 mei 2010
Updates van studierecords
Laatste update geplaatst (Schatting)
7 maart 2016
Laatste update ingediend die voldeed aan QC-criteria
8 februari 2016
Laatst geverifieerd
1 februari 2016
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Parkinson-stoornissen
- Basale ganglia-ziekten
- Bewegingsstoornissen
- Synucleïnopathieën
- Neurodegeneratieve ziekten
- Ziekte van Parkinson
- Fysiologische effecten van medicijnen
- Micronutriënten
- Vitaminen
- Behoudsmiddelen voor botdichtheid
- Calciumregulerende hormonen en middelen
- Vitamine D
- Cholecalciferol
- Calcium
Andere studie-ID-nummers
- B7051-W
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .